​Breathtec Biomedical (BTHCF) Provides Development Update on Breathalyzer for Disease Detection

Spotlight Companies |

Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) is pleased to report on the development of its Breathtec Disease Detection Breathalyzer (“V2”) prototype based on the FAIMS (field asymmetric waveform ion mobility spectrometry) technology. In collaboration with Cannabix Technologies (CSE:BLO), the V2 prototype is now complete. The new device, classified as “V3” is designed to operate both independently with its own self-contained FAIMS detector, or coupled in tandem directly to a triple-quadrupole Mass Spectrometer (MS) device.The device also incorporates several technological enhancements, including a modular design for faster iterative development, as well as size reduction into a compact Point-of-Care (POC) design.

Preliminary bench testing indicates a direct correlation between the V3 device and the MS. The MS is considered the gold standard in biomarker detection and it is anticipated that any results from a breathalyzer for disease detection will have to be independently verified by MS.

The Company plans to further develop the V3 device and implement findings from ongoing research conducted on biomarkers found in the breath that are associated with diseases, and continue on the path of developing hand-held Breathtec Disease Detection Breathalyzers to be non-invasive and highly accurate detection methods for various diseases.



CTO Mike Costanzo states, “Breathtec Biomedical remains dedicated to the development of a highly sensitive breathalyzer for disease detection. With our collaboration with Cannabix and the Vancouver Technical Team, we can expedite the testing and analysis of biomarkers related to disease.”

Update on Management

Breathtec Biomedical is currently in advanced talks with candidates for CEO to lead Breathtec Biomedical and will make announcements as the company progresses in its evaluation of candidates.

ON BEHALF OF THE BOARD
“Michael Sadhra”
Chief Financial Officer & Director

ABOUT BREATHTEC BIOMEDICAL INC.
Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of airborne analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of certain pathogens. Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry. For more information, visit www.breathtecbiomedical.com.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
BTH:CNX Breathtec BioMedical Inc 0.18 -0.01 -5.41 17,300
BTHCF Breathtec Biomedical Inc 0.14 -0.01 -6.41 5,500

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…